STO (ATCC® CRL-1503)

Organism: Mus musculus, mouse  /  Cell Type: fibroblast  /  Tissue: embryo  /  Disease: Cancer

Organism Mus musculus, mouse
Tissue
embryo
Cell Type fibroblast
Product Format frozen
Morphology fibroblast
Culture Properties adherent
Biosafety Level 1
Disease Cancer
Age embryo
Strain SIM (Sandos Inbred Mice)
Applications
The cell line is used routinely to prepare feeder layers by irradiation or mitomycin C treatment. Such populations are then employed for maintenance of stock teratocarcinoma stem cells (see ATCC CRL-1535 and CRL-1566) in the undifferentiated state.
This cell line is a suitable transfection host.
Storage Conditions liquid nitrogen vapor phase
Derivation
The STO cell line was derived by A. Bernstein, Ontario Cancer Institute, Toronto, Canada from a continuous line of SIM mouse embryonic fibroblasts.
The population which was selected for 6-thioguanine and ouabain resistance is sensitive to HAT medium and is HPRT negative.
Comments
The cells have been tested and found negative for ectromelia virus (mousepox).
Complete Growth Medium The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Volumes are given for a 75 cm2 flask. Increase or decrease the amount of dissociation medium needed proportionally for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
    Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:10 is recommended
    Medium Renewal: 2 to 3 times per week
    Cryopreservation
    Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
    Storage temperature: liquid nitrogen vapor phase
    Culture Conditions
    Temperature: 37°C
    Name of Depositor G Martin
    References

    Martin GR, Evans MJ. Differentiation of clonal lines of teratocarcinoma cells: formation of embryoid bodies in vitro. Proc. Natl. Acad. Sci. USA 72: 1441-1445, 1975. PubMed: 1055416

    Teratomas and Differentiation, eds. Michael I. Sherman and David Solter, 13–14. New York: Academic Press, 1975.

    Martin GR, Evans MJ. Multiple differentiation of clonal teratocarcinoma stem cells following embryoid body formation in vitro. Cell 6: 467-474, 1975.

    Martin GR, et al. The development of cystic embryoid bodies in vitro from clonal teratocarcinoma stem cells. Dev. Biol. 61: 230-244, 1977. PubMed: 590624

    The line was derived from a continuous line of SIM mouse embryonic fibroblasts by A. Bernstein at the Ontario Cancer Institute.

    Basic Documentation
    References

    Martin GR, Evans MJ. Differentiation of clonal lines of teratocarcinoma cells: formation of embryoid bodies in vitro. Proc. Natl. Acad. Sci. USA 72: 1441-1445, 1975. PubMed: 1055416

    Teratomas and Differentiation, eds. Michael I. Sherman and David Solter, 13–14. New York: Academic Press, 1975.

    Martin GR, Evans MJ. Multiple differentiation of clonal teratocarcinoma stem cells following embryoid body formation in vitro. Cell 6: 467-474, 1975.

    Martin GR, et al. The development of cystic embryoid bodies in vitro from clonal teratocarcinoma stem cells. Dev. Biol. 61: 230-244, 1977. PubMed: 590624

    The line was derived from a continuous line of SIM mouse embryonic fibroblasts by A. Bernstein at the Ontario Cancer Institute.